TSC 205
Alternative Names: TSC-205Latest Information Update: 10 May 2023
At a glance
- Originator TScan Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Anal cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer